Personal information

Websites & social links

Research Gate
LinkedIn

Other IDs

ResearcherID: KZU-2096-2024

Activities

Collapse all

Employment (1)

Icahn School of Medicine at Mount Sinai: New York, New York, US

2021-10-25 to present | Senior Associate Researcher (Hematology and Medical Oncology)
Employment
Source: Self-asserted source
Andrew Davis

Education and qualifications (3)

University of California, San Francisco: San Francisco, US

2024-09-03 to present | Ph.D.
Education
Source: Self-asserted source
Andrew Davis

University of Southern California: Los Angeles, California, US

2017-08 to 2018-12 | MS Stem Cell Biology and Regenerative Medicine
Education
Source: Self-asserted source
Andrew Davis

University of Southern California: Los Angeles, California, US

2014-08 to 2017-12 | BS Health Promotion and Disease Prevention
Education
Source: Self-asserted source
Andrew Davis

Works (6)

S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM-BLAST PHASE (MPN-BP) INITIATING CELLS AND PROLONGS LEUKEMIA-FREE SURVIVAL (LFS) IN AN MPN-BP PDX MODEL

HemaSphere
2023-08-08 | Conference paper
DOI: 10.1097/01.hs9.0000967740.44843.f0
Part of ISSN: 2572-9241
Contributors: Xiaoli Wang; Cing Siang Hu; Andrew Davis; Cecile Krejsa; Ronald Hoffman
Source: Self-asserted source
Andrew Davis

Transcriptional and Epigenetic Dysregulation Drives Erythroid and Megakaryocyte Differentiation Bias in the Spleens of Patients with Advanced Myelofibrosis

Blood
2022-11-15 | Conference abstract
DOI: 10.1182/blood-2022-170220
Part of ISSN: 0006-4971
Part of ISSN: 1528-0020
Contributors: Rebecca Austin; Madeline Kowalski; Xiaoli Wang; Bettina Nadorp; Audrey Lasry; Zhengxi Sun; Julia Rojo-Tomillo; Andrew Davis; Dimitrios Papaioannou; Rahul Satija et al.
Source: Self-asserted source
Andrew Davis

Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase

JCI Insight
2022-04-22 | Journal article | Author
DOI: 10.1172/jci.insight.156534
Part of ISSN: 2379-3708
Contributors: Xiaoli Wang; Raajit K. Rampal; Cing Siang Hu; Joseph Tripodi; Noushin Farnoud; Bruce Petersen; Michael R. Rossi; Minal Patel; Erin McGovern; Vesna Najfeld et al.
Source: Self-asserted source
Andrew Davis

Gene modified CD34+ cells with increased ALDH1 expression confers in vitro protection against cyclophosphamide

Unpublished
2020 | Conference poster
DOI: 10.13140/RG.2.2.15508.32642
Contributors: Ramesh Halder; Andrew Davis; Tung X Nguyen; ; ; Joseph Cohen; ; David Hardy; Mark Dybul; Serhat Gumrukcu
Source: Self-asserted source
Andrew Davis

Increased Engraftment of Gene Modified HSPCs Overexpressing ALDH1 In Vivo

Unpublished
2020 | Conference poster
DOI: 10.13140/RG.2.2.35640.98560
Contributors: Serhat Gumrukcu; Philippe Gallay; Tung X Nguyen; ; Joseph Cohen; ; Ramesh Halder; ; Andrew DAvis; et al.
Source: Self-asserted source
Andrew Davis

Laminin-1 induces endocytosis of 67KDa laminin receptor and protects Neuroscreen-1 cells against death induced by serum withdrawal

Biochemical and Biophysical Research Communications
2018-01 | Journal article
DOI: 10.1016/j.bbrc.2017.11.015
Part of ISSN: 0006-291X
Contributors: Rayudu Gopalakrishna; Usha Gundimeda; Sarah Zhou; Helena Bui; Andrew Davis; Thomas McNeill; William Mack
Source: Self-asserted source
Andrew Davis
How many people are using ORCID?